Results 81 to 90 of about 1,068 (138)

Ciprofloxacin‐Induced Near‐Total Toxic Epidermal Necrolysis Complicated by Upper Gastrointestinal Bleeding: A Case Report With ALDEN‐Based Causality Assessment

Clinical Case Reports, Volume 14, Issue 8, August 2026.
ABSTRACT Toxic epidermal necrolysis (TEN) is a rare but life‐threatening mucocutaneous adverse drug reaction characterized by widespread epidermal necrosis and detachment with significant mucosal involvement. We report a case of near total (80%–90%) body surface area TEN in a previously healthy 30‐year‐old man that developed approximately 5 days after ...
Amanuel D. Wakoya, Alemu B. Mesekere, Seid A. abdullahi, Misale B. Tesfaye, Zeynu H. Endris, Zelalem G. Demissie, Tibebu G. Haile   +6 more
wiley   +1 more source

New Insights Into Immunomodulatory Strategies for Drug Hypersensitivity Reactions: An EAACI Task Force Report

Clinical and Translational Allergy, Volume 16, Issue 8, August 2026.
ABSTRACT Drug hypersensitivity reactions (DHRs) are a global health concern and remain challenging to investigate owing to the heterogeneity of endotypes and phenotypes, as well as the lack of standardized biomarkers. Until recently, strict drug avoidance was the only management strategy for severe DHRs.
Ana Maria Copaescu, Valentina Gueli, Jitesh Chahuan, Waad Albalawi, Giovanna Sfriso, Mattia Giovannini, Leticia de las Vecillas, Aspasia Karavelia, Marina Labella, Ruben Fernandez‐Santamaria, Francesca Mori, Lene H. Garvey, Patrizia Bonadonna, Maria Jose Torres   +13 more
wiley   +1 more source

Population Genomics Insights into Pharmacogenomic Differentiation Between East Asians and Europeans

Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 510-519, August 2026.
Genetic variation contributes substantially to interindividual and interpopulation differences in drug response, yet most pharmacogenomic studies remain biased toward European populations. Here, we systematically assessed pharmacogenomic variation across East Asians (EAS) and Europeans (EUR) using public genomic datasets and investigated the potential ...
Sihan Chen, Hongpu Chen, Shuhua Xu
wiley   +1 more source

Targeted Interventions in HAM/TSP: Emerging Therapies and Future Directions – A Narrative Review

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aim Human T‐Lymphotropic virus type 1 (HTLV‐1) infection can lead to HTLV‐1‐associated myelopathy/tropical spastic paraparesis (HAM/TSP), a debilitating chronic neurological disease characterized by progressive lower limb spasticity and autonomic dysfunction.
Meygol Mirzaei Rezaei, Mahdi Khosravi Nia, Kasra Allaei Rouzbahani, Maryam Kazemi, Negar Asghari Hosori, Mehdi Norouzi, Farzaneh Sotoudegan, Narges Eslami, Negar Ariamand, Vahid Shahnavaz, Arash Letafati, Sayed‑Hamidreza Mozhgani   +11 more
wiley   +1 more source

Utilization of Suprathel® in delayed surgical management of toxic epidermal necrolysis (TEN): A case report

Burns Open
Given the lack of established practice guidelines for the management of cutaneous symptoms associated with toxic epidermal necrolysis, treatments range from various dressings to skin substitutes.
Isabella Lipkin, Michelle Hughes, W.B. Hughes   +2 more
doaj   +1 more source

Investigation of the Prevalence of the HLA‐B*15:02 Allele in the Asian Populations: A Comprehensive Analysis Through Using AFND

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims The HLA‐B*15:02 allele is related to a high risk of severe cutaneous adverse drug reactions (SCARs) in patients taking certain antiepileptic drugs. However, its prevalence in the Asian population and the number of drugs linked to SCARs due to the carriage of this variant are relatively underexplored.
Mohitosh Biswas, Murshadul Alam Murad, Maliheh Ershadian, Chonlaphat Sukasem   +3 more
wiley   +1 more source

A fatal case of cutaneous adverse drug-induced toxic epidermal necrolysis associated with severe rhabdomyolysis

Annals of Saudi Medicine, 2012
Toxic epidermal necrolysis represents an immunologic reaction to a foreign antigen and is most often caused by drugs. Atorvastatin, a blood cholesterol–lowering agent, is a recognized cause of rhabdomyolysis; while naproxen, a widely used nonsteroidal ...
Sheik Oaleed Noordally, Schoeb Sohawon, Julien Vanderhulst, Ruth Duttmann, Francis Corazza, Jacques Devriendt   +5 more
doaj   +1 more source

Leveraging Administrative Health Data to Capture Rare Adverse Drug Reactions: Identifying Pediatric Patients With Trimethoprim‐Sulfamethoxazole Acute Respiratory Distress Syndrome

Pharmacology Research &Perspectives, Volume 14, Issue 4, August 2026.
ABSTRACT Rare adverse drug reactions (ADRs) are underrecognized and underreported in the electronic medical record (EMR). These events often require clinical review, making systematic identification challenging. The study aim was to develop an approach to prioritize identification and validation of a rare ADR to trimethoprim‐sulfamethoxazole causing ...
Keith Feldman, Jenna O. Miller, Katherine Doane, Laura Loftis, James W. Antoon, Kevin J. Downes, Jennifer L. Goldman   +6 more
wiley   +1 more source

Toxic Epidermal Necrolyisis and Sepsis

European Journal of Case Reports in Internal Medicine, 2016
A 63-year-old male patient suffered from myalgia, arthralgia cough and erythematous macules, with confluence to the thorax, limbs, thighs and the scrotum. The erythematous macules evolved to blisters with a positive Nikolsky’s sign. A cutaneous biopsy revealed satellite cell necrosis. Administration of immunoglobulins resulted in a favourable evolution
Alves, Daniela, Lourenço, Nulita, Franco, Daniela, Calmeiro, Eufémio, Silva, Rosa   +4 more
openaire   +4 more sources

Efficacy and Tolerability of Weekly Bortezomib, Lenalidomide, and Dexamethasone Protocols in Transplant‐Ineligible Newly Diagnosed Myeloma: An Australian Real‐World, Multicenter Study

Asia-Pacific Journal of Clinical Oncology, Volume 22, Issue 4, Page 573-583, August 2026.
RVD with weekly bortezomib dosing in real‐world newly diagnosed transplant‐ineligible myeloma shows comparable efficacy and reduced toxicity compared to twice‐weekly trial protocols. ABSTRACT Background Lenalidomide, bortezomib, and dexamethasone (RVD) remains a standard of care regimen for newly diagnosed multiple myeloma in centers without access to ...
Samantha Kurniawan, Angela Hwang, Nicole Wong Doo, Tracy King, Christian Bryant, Jennifer Zhang, Kristina Whelan, Parisa Fani‐Molky, Giselle Kidson‐Gerber, Annmarie Bosco, Nada Hamad, Gurdeep Parmar, Fiona Kwok, Sam Lai, Silvia Ling, P. Joy Ho, Georgia McCaughan, Adam Bryant   +17 more
wiley   +1 more source